Delivery Order SPE2DB22D2007-SPE2DB25FJ4AQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 11, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody biologic therapy indicated for treating systemic...
- The Defense Logistics Agency awarded a $9,248.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. Benlysta (belimumab) is a biologic immunosuppressant used primarily to treat systemic lupus erythematosus and other autoimmune conditions. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a $18,458.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Benlysta 200 mg/mL syringes. This is a non-set-aside competitive award with an ultimate completion date of September 3, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic immunosuppressant used primarily in the treatment of systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta (belimumab) is a monoclonal antibody used to treat...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with fulfillment performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic medication used primarily in the treatment of systemic lupus...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,629.64 by the Defense Logistics Agency (DLA) on July 29, 2025, for the supply of Benlysta 400 mg vials with an ultimate completion date of August 19, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is located at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,076.40 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL syringes. This competitively awarded, firm fixed-price contract was issued on August 12, 2025, with an ultimate completion date of September 3, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $6,152.80 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Benlysta 200 mg/ml syringes. This competitive award, utilizing firm fixed-price contract terms, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4AQDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,888.54 to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials, with an ultimate completion date of September 9, 2025. This firm fixed price delivery order represents a non-set-aside competitive award issued on August 18, 2025. Benlysta (belimumab) is a monoclonal antibody treatment used for systemic lupus erythematosus, a severe autoimmune disease, and its procurement through DLA supports military and federal healthcare system requirements. This delivery order operates under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical supply vehicle running through December 2026. As a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, AmerisourceBergen maintains a substantial role in the federal medical supply chain, providing a broad portfolio of medications and medical supplies to support military healthcare programs globally. The company's contract activity demonstrates consistent capability to fulfill federal procurement requirements for specialized pharmaceutical products across multiple therapeutic domains through competitive award mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.9k | 8/18/25 |